1 report

  • May 26, 2016: Flexion Therapeutics Receives Positive Guidance from FDA on New Drug Application (NDA) Submission for Zilretta for Osteoarthritis of the Knee
  • Mar 10, 2016: Flexion Reports Year-End 2015 Financial Results

The data from these trials are consistent with Zilretta providing meaningful and durable pain relief.

  • Arthritis
  • Tricyclic Antidepressant
  • United States
  • Company
  • Flexion Therapeutics, Inc.